Insight Molecular Diagnostics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Insight Molecular Diagnostics Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 98% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 323% in 3 years; of every extra $100 of sales, $732 became extra profit. Higher than 96% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-16.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 56% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$732Sales grew 323% in 3 years; of every extra $100 of sales, $732 became extra profit.
Higher than 96% of Healthcare companies in United States.
Asset Productivity Ratio
+323% / -74%In 3 years sales changed by +323% while total assets changed by -74%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-12.3×Operating cash was negative last year, while some debt falls due within a year.
Higher than 53% of Healthcare companies in United States.
Cash Cushion Ratio
+9%Cash, after subtracting all debt, equals 9% of its market value (net cash).
Lower than 51% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 98% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Insight Molecular Diagnostics Inc. made a loss over the last year. Insight Molecular Diagnostics Inc. owes $1.72 for every $1 it owns. Insight Molecular Diagnostics Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossInsight Molecular Diagnostics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-4.36Insight Molecular Diagnostics Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$93 MThe total market value of all of Insight Molecular Diagnostics Inc.'s shares at today's price (share price × number of shares), smaller than 67% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeInsight Molecular Diagnostics Inc.'s net worth is negative ($21 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.72×Insight Molecular Diagnostics Inc. owes $1.72 for every $1 it owns, so it owes more than it owns, higher than 95% of Healthcare companies in United States.
Dividend yield
NoneInsight Molecular Diagnostics Inc. does not currently pay a dividend.
Revenue growth
+116%Revenue rose 116% in the year to Dec 2025, and grew 62% a year on average over 3 years.
Profit growth
LossInsight Molecular Diagnostics Inc. made a loss in each of the last two years.
Profit margin
-1238.5%Insight Molecular Diagnostics Inc. lost $1239 for every $100 of revenue.
Interest cover
Not coveredInsight Molecular Diagnostics Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashInsight Molecular Diagnostics Inc. held $8 M more cash than debt (net cash) at Dec 2025.
Questions
How much does Insight Molecular Diagnostics Inc. owe compared with what it owns?
Insight Molecular Diagnostics Inc. owes $1.72 for every $1 it owns, so it owes more than it owns, higher than 95% of Healthcare companies in United States.
Does Insight Molecular Diagnostics Inc. pay a dividend?
No. Insight Molecular Diagnostics Inc. does not currently pay a dividend.
Is Insight Molecular Diagnostics Inc.'s revenue growing?
Revenue rose 116% in the year to Dec 2025, and grew 62% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.